tiprankstipranks
Trending News
More News >
Regeneron (REGN)
NASDAQ:REGN
Advertisement

Regeneron (REGN) AI Stock Analysis

Compare
5,024 Followers

Top Page

REGN

Regeneron

(NASDAQ:REGN)

Select Model
Select Model
Select Model
Outperform 79 (OpenAI - 4o)
Rating:79Outperform
Price Target:
$749.00
▲(14.72% Upside)
Regeneron's strong financial performance and robust earnings call results are the primary drivers of its stock score. The company's solid balance sheet and cash flow position support its growth prospects. Technical indicators suggest bullish momentum, though caution is advised due to potential overbought conditions. Valuation metrics indicate the stock is fairly valued within its sector.
Positive Factors
Revenue Growth
Dupixent's strong sales growth indicates robust demand and market penetration, supporting Regeneron's revenue expansion and long-term growth prospects.
R&D Pipeline Progress
Advancements in the R&D pipeline demonstrate Regeneron's commitment to innovation and potential for future product launches, enhancing competitive positioning.
Collaboration Agreement
The collaboration with ModeX Therapeutics leverages Regeneron's expertise in multispecific antibodies, potentially expanding its therapeutic offerings and market reach.
Negative Factors
EYLEA Affordability Issues
Affordability challenges for EYLEA could limit its market growth and impact Regeneron's revenue from this key product, necessitating strategic adjustments.
FDA Setback for EYLEA HD
FDA setbacks for EYLEA HD could delay product enhancements and affect sales momentum, impacting Regeneron's competitive edge in the ophthalmology market.
EYLEA U.S. Sales Decline
The decline in EYLEA's U.S. sales suggests potential market saturation or increased competition, which could pressure Regeneron's revenue growth from this segment.

Regeneron (REGN) vs. SPDR S&P 500 ETF (SPY)

Regeneron Business Overview & Revenue Model

Company DescriptionRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of serious conditions. Headquartered in Tarrytown, New York, Regeneron operates primarily in the biotechnology sector, developing drugs in therapeutic areas including ophthalmology, immunology, oncology, and cardiovascular diseases. The company is known for its flagship products such as Eylea, a treatment for eye diseases, and Dupixent, used for various allergic and inflammatory conditions.
How the Company Makes MoneyRegeneron generates revenue primarily through the sale of its proprietary drugs. The company's key revenue streams include product sales from its leading therapies, notably Eylea and Dupixent. Eylea has established itself as a significant revenue driver in the ophthalmology market, while Dupixent has gained traction in the immunology space. Additionally, Regeneron engages in collaborative partnerships and licensing agreements with other pharmaceutical companies, which can provide milestone payments and royalties based on sales. The company's robust pipeline of drug candidates in various stages of development also holds the potential for future revenue growth, particularly as new products gain regulatory approval and enter the market.

Regeneron Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.
Chart InsightsRegeneron's recent revenue trends highlight strong growth in the Collaboration segment, driven by strategic partnerships, while Net Product revenue shows volatility, reflecting challenges with EYLEA sales. The earnings call underscores robust sales growth for Dupixent and Libtayo, offset by EYLEA's decline due to competitive pressures and regulatory delays. The company's strategic pivot to EYLEA HD and a robust R&D pipeline with 45 candidates signal potential future growth, despite current hurdles. Investors should watch for updates on FDA inspections and pivotal data releases in key therapeutic areas.
Data provided by:Main Street Data

Regeneron Earnings Call Summary

Earnings Call Date:Oct 28, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Jan 30, 2026
Earnings Call Sentiment Neutral
Regeneron demonstrated strong sales growth in key products like Dupixent and Libtayo, along with significant R&D pipeline progress. However, challenges such as affordability issues for EYLEA and FDA-related setbacks tempered some positive outcomes. Overall, the company shows a robust financial position and commitment to innovation, but faces operational hurdles that need addressing.
Q3-2025 Updates
Positive Updates
Dupixent Sales Growth
Worldwide net product sales for Dupixent increased by 26% compared to the third quarter of last year. In the U.S., Dupixent net product sales grew 28%.
Libtayo Sales and FDA Approval
Global Libtayo net product sales were $365 million, up 24% on a constant currency basis. The FDA approved Libtayo for high-risk adjuvant cutaneous squamous cell carcinoma.
EYLEA HD Performance
EYLEA HD in the U.S. grew by 10%, with net product sales reaching $431 million, an all-time high.
R&D Pipeline Progress
Positive Phase III or registration-enabling data for six distinct programs in immunology, neurology, allergy, and rare diseases.
Regeneron's Financial Strength
Generated $3.2 billion in free cash flow through the first 9 months of 2025, with cash and marketable securities less debt of approximately $16 billion.
Negative Updates
EYLEA Affordability Issues
Affordability issues continue to dampen branded anti-VEGF category growth, with EYLEA's match program receiving less than $1 million in donations.
FDA Complete Response Letter for EYLEA HD
FDA issued a complete response letter for the prefilled syringe supplemental BLA due to unresolved inspection findings at Catalent.
EYLEA U.S. Sales Decline
EYLEA's third quarter U.S. net sales decreased 10% quarter-over-quarter, reflecting a commensurate decline in unit demand.
Company Guidance
During the call, Regeneron Pharmaceuticals provided guidance indicating robust growth for several key products. In the third quarter of 2025, Dupixent's global net sales reached $4.9 billion, reflecting a 26% increase over the previous year. Libtayo's sales grew by 24% to $365 million worldwide, with a 12% increase in the U.S., bolstered by its recent FDA approval for high-risk adjuvant cutaneous squamous cell carcinoma. EYLEA HD's U.S. net product sales rose to $431 million, marking a 10% growth. The company anticipates moderate to high single-digit sequential demand growth for EYLEA HD in the fourth quarter. Regeneron also highlighted its intention to invest over $7 billion in manufacturing infrastructure in the U.S. and plans to advance multiple substantial registrational programs in 2026, with a forecasted mid-teens percentage increase in R&D spending.

Regeneron Financial Statement Overview

Summary
Regeneron exhibits strong financial health with impressive revenue growth and profitability metrics. The company maintains a high gross profit margin and a solid balance sheet with low leverage. Cash flows are robust, supporting ongoing operations and potential investments, despite minor fluctuations in margins and cash flow ratios.
Income Statement
85
Very Positive
Regeneron has demonstrated strong revenue growth with a 23.6% increase in the TTM period, indicating robust demand for its products. The company maintains high profitability with a gross profit margin of 85.4% and a net profit margin of 32.1%, showcasing efficient cost management. However, there is a slight decline in EBIT and EBITDA margins compared to previous years, which could indicate rising operational costs or increased competition.
Balance Sheet
88
Very Positive
The balance sheet is solid with a low debt-to-equity ratio of 0.087, reflecting conservative financial leverage and a strong equity base. Return on equity remains healthy at 15.3%, indicating effective use of shareholder funds. The equity ratio is also strong, suggesting a stable financial position with a significant portion of assets financed by equity.
Cash Flow
82
Very Positive
Regeneron's cash flow is robust, with a positive free cash flow growth rate of 8.1% in the TTM period. The operating cash flow to net income ratio of 1.15 indicates strong cash generation relative to earnings. However, the free cash flow to net income ratio has slightly decreased, suggesting potential reinvestment needs or increased capital expenditures.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.25B14.20B13.12B12.17B16.07B8.50B
Gross Profit12.17B12.23B10.87B10.47B13.35B7.14B
EBITDA5.71B5.32B4.69B5.26B9.67B4.10B
Net Income4.58B4.41B3.95B4.34B8.08B3.51B
Balance Sheet
Total Assets40.17B37.76B33.08B29.21B25.43B17.16B
Cash, Cash Equivalents and Short-Term Investments8.44B9.01B10.84B7.74B5.69B3.59B
Total Debt2.71B2.70B2.70B2.70B2.70B2.70B
Total Liabilities9.21B8.41B7.11B6.55B6.67B6.14B
Stockholders Equity30.96B29.35B25.97B22.66B18.77B11.03B
Cash Flow
Free Cash Flow4.15B3.66B3.67B4.42B6.53B2.00B
Operating Cash Flow5.07B4.42B4.59B5.01B7.08B2.62B
Investing Cash Flow-498.80M-2.47B-3.19B-3.78B-5.38B-70.60M
Financing Cash Flow-4.07B-2.20B-1.79B-1.01B-1.01B-1.97B

Regeneron Technical Analysis

Technical Analysis Sentiment
Positive
Last Price652.91
Price Trends
50DMA
579.65
Positive
100DMA
562.42
Positive
200DMA
595.51
Positive
Market Momentum
MACD
12.02
Negative
RSI
72.63
Negative
STOCH
92.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REGN, the sentiment is Positive. The current price of 652.91 is above the 20-day moving average (MA) of 585.41, above the 50-day MA of 579.65, and above the 200-day MA of 595.51, indicating a bullish trend. The MACD of 12.02 indicates Negative momentum. The RSI at 72.63 is Negative, neither overbought nor oversold. The STOCH value of 92.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for REGN.

Regeneron Risk Analysis

Regeneron disclosed 47 risk factors in its most recent earnings report. Regeneron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Regeneron Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$17.70B15.1330.39%18.09%3563.21%
$68.61B15.6715.19%0.40%2.89%0.50%
$50.39B38.9824.75%89.58%
$106.97B29.8222.77%10.38%
$63.13B-195.21-257.82%5.01%-330.09%
$24.85B-1.81%7.51%30.53%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
REGN
Regeneron
652.91
-265.94
-28.94%
ALNY
Alnylam Pharma
481.59
200.10
71.09%
INCY
Incyte
90.18
16.25
21.98%
VRTX
Vertex Pharmaceuticals
417.21
-57.87
-12.18%
ARGX
Argenx Se
821.97
270.26
48.99%
BNTX
BioNTech SE
103.35
-10.59
-9.29%

Regeneron Corporate Events

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence
Oct 29, 2025

Study Overview: Regeneron Pharmaceuticals recently completed a study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aimed to describe and estimate the incidence of retinal vasculitis (RV) events among patients receiving aflibercept intravitreal (IVT) therapy in US clinical practice, highlighting the significance of monitoring adverse effects in real-world settings.

Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges
Oct 29, 2025

Regeneron Pharmaceuticals faces significant risks due to tariffs and trade restrictions, which could materially impact its operations and financial health. The imposition of tariffs by the United States and other countries, including potential new tariffs on pharmaceutical imports, poses a threat to the company’s supply chain and cost structure. Although pharmaceutical products are currently exempt from certain tariffs, the raw materials necessary for production are not, leading to increased operational costs. Additionally, ongoing investigations and trade agreements could further complicate the situation, potentially resulting in higher tariffs and retaliatory measures that may adversely affect Regeneron’s financial condition.

Regeneron Pharmaceuticals Reports Q3 2025 Financial Results
Oct 29, 2025

Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes innovative medicines for serious diseases, utilizing proprietary technologies to advance drug development across various therapeutic areas. In its third quarter of 2025, Regeneron reported a 1% increase in revenues, reaching $3.75 billion, with notable growth in Dupixent sales and new FDA approvals for key treatments. The company’s financial performance was marked by a 9% increase in GAAP net income, although non-GAAP net income saw a decline. Regeneron highlighted strategic advancements, including FDA approvals for Libtayo and Evkeeza, and promising clinical trial results in several therapeutic areas. Looking ahead, Regeneron remains focused on advancing its late-stage pipeline and maintaining solid financial performance, with continued investments in innovation and shareholder value.

Regeneron Earnings Call: Strong Growth Amid Challenges
Oct 29, 2025

Regeneron Pharmaceuticals’ recent earnings call painted a picture of a company experiencing robust growth in key areas, yet facing some operational challenges. The sentiment was largely positive, with strong sales growth in products like Dupixent and Libtayo, and significant progress in their R&D pipeline. However, issues such as affordability challenges for EYLEA and FDA-related setbacks highlighted areas needing attention. Overall, Regeneron maintains a strong financial position and a commitment to innovation.

Regeneron Initiates Promising Study on REGN7041 for Eye Inflammation
Oct 27, 2025

Regeneron Pharmaceuticals is initiating a study titled ‘A Phase 1/2a Study of REGN7041 (Anti-CD3 Monoclonal Antibody) in Participants With Active Noninfectious Uveitis Affecting the Posterior Segment.’ The study aims to assess the safety and tolerability of the experimental drug REGN7041 in treating inflammation inside the eye without infection. This first-in-human trial will explore potential side effects, drug levels in blood and eye fluid, and the body’s immune response to the drug.

Regeneron’s New Parkinson’s Study: A Potential Game-Changer?
Oct 27, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a first-in-human study titled ‘First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Intrathecally Administered ALN-SNCA in Participants With Early Parkinson’s Disease.’ The study aims to assess the safety and tolerability of ALN-SNCA, an experimental drug, in individuals with early-stage Parkinson’s disease, a condition characterized by the harmful accumulation of α-synuclein protein in the brain.

Regeneron’s New Phase 3 Study: A Potential Game Changer in VTE Prevention?
Oct 27, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)’. The study aims to evaluate the effectiveness of REGN7508 in preventing venous thromboembolism (VTE) in adults undergoing elective total knee replacement surgery, compared to acetylsalicylic acid (ASA).

Regeneron Pharmaceuticals Advances with ALN-CFB Study for PNH Treatment
Oct 27, 2025

Regeneron Pharmaceuticals is conducting a pivotal study titled ‘A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ALN-CFB, an Investigational siRNA Therapeutic Against Complement Factor B, in Participants With Paroxysmal Nocturnal Hemoglobinuria and Persistent Anemia on Approved C5-Inhibitor Therapy.’ This study aims to assess the safety and tolerability of ALN-CFB in adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who continue to experience anemia despite being on a C5 inhibitor. The study’s significance lies in its potential to offer a new therapeutic option for this patient population.

Regeneron and Sanofi Launch New Study on Dupilumab for Children’s Growth and Bone Health
Oct 27, 2025

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to <12 Years of Age With Severe Atopic Dermatitis Treated With Dupilumab.' The study aims to evaluate whether dupilumab, an approved treatment for atopic dermatitis, can improve growth and bone strength in children with severe cases that are not well-managed by topical treatments. Additionally, the study will monitor potential side effects of dupilumab.

Regeneron Launches New Study on Anticoagulant Drugs for Atrial Fibrillation
Oct 27, 2025

Regeneron Pharmaceuticals has announced a new clinical study titled ‘A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)’. The study aims to assess the safety and efficacy of two experimental drugs, REGN7508 and REGN9933, in preventing blood clots in patients with atrial fibrillation, comparing their effects to the existing drug, Apixaban.

Regeneron and Sanofi’s Phase 3 COPD Study Completes: Market Implications
Oct 27, 2025

Study Overview: Regeneron Pharmaceuticals and Sanofi have completed a Phase 3 clinical study titled Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). The study aimed to assess the efficacy, safety, and tolerability of Itepekimab in reducing acute exacerbations of COPD in former smokers, with secondary objectives including improvements in pulmonary function and quality of life.

Regeneron and Sanofi’s Phase 3 COPD Study Completes: Market Implications Ahead
Oct 27, 2025

Regeneron Pharmaceuticals and Sanofi recently completed a Phase 3 study titled ‘Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).’ The study aimed to assess the effectiveness of itepekimab in reducing the rate of acute COPD exacerbations in former smokers, alongside evaluating its impact on pulmonary function, respiratory symptoms, and overall quality of life.

Regeneron’s Garetosmab Study Withdrawn: Implications for Investors
Oct 27, 2025

Study Overview: Regeneron Pharmaceuticals initiated a study titled ‘Randomized, Double-Blind, Placebo-Controlled Study of Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Garetosmab in Men and Post-Menopausal Women With Obesity Who Are Otherwise Healthy.’ The study aimed to evaluate the safety and tolerability of garetosmab in healthy obese individuals, focusing on its effects on blood clotting, hormone levels, and potential antibody development against the drug.

Regeneron’s bbT369 Study Termination: Implications for Investors
Oct 27, 2025

Regeneron Pharmaceuticals has been conducting a clinical study titled ‘A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin’s Lymphoma (NHL).’ The study aims to evaluate the safety and efficacy of bbT369, a novel CAR T cell therapy, in patients with relapsed or refractory B cell NHL, a significant area of unmet medical need.

Regeneron’s New Phase 3 Study on Mibavademab: A Potential Game-Changer for Generalized Lipodystrophy
Oct 24, 2025

Regeneron Pharmaceuticals is conducting a critical study titled ‘A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy.’ The study aims to evaluate the effectiveness and safety of mibavademab, a new drug, in treating Generalized Lipodystrophy (GLD) in both adults and children. This research is significant as it explores the drug’s impact on blood sugar, triglycerides, liver fat, and potential antibody development against the drug.

Regeneron Launches New Study on Mibavademab for Monogenic Obesity
Oct 24, 2025

Regeneron Pharmaceuticals is initiating a new clinical study titled ‘An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene.’ The study aims to evaluate the effectiveness and safety of mibavademab in treating monogenic obesity, a condition caused by leptin gene mutations that impair hunger regulation. Key objectives include assessing weight control, drug concentration in the blood, and potential side effects.

Regeneron Halts Hypertension Drug Study: Market Implications
Oct 23, 2025

Regeneron Pharmaceuticals recently updated its clinical study titled A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Multiple Dose Regimen of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Participants With Uncontrolled Hypertension. The study aimed to assess the effectiveness of REGN5381 in reducing blood pressure in patients with uncontrolled hypertension. Key objectives included evaluating the drug’s safety, side effects, and pharmacokinetics.

Regeneron’s Cemiplimab Study: Real-World Insights and Market Impact
Oct 16, 2025

Study Overview: The Cemiplimab Survivorship Epidemiology (CASE) Study, conducted by Regeneron Pharmaceuticals, aims to evaluate the effectiveness and safety of cemiplimab in treating advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) in real-world settings. The study focuses on patient outcomes, safety, and treatment patterns, providing valuable insights into the drug’s performance outside of controlled clinical trials.

Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
Oct 10, 2025

Study Overview: Regeneron Pharmaceuticals, in collaboration with Bayer, has completed an extension study titled An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090. The study aims to assess the long-term effects of treatments administered in the FIREFLEYE study, focusing on the condition known as Retinopathy of Prematurity (ROP), a serious eye disorder affecting premature infants.

Regeneron Completes Study on Aflibercept’s Safety in Real-World Settings
Oct 10, 2025

Study Overview: Regeneron Pharmaceuticals recently completed a study titled ‘Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study.’ The study aimed to estimate the incidence of Retinal Vasculitis (RV) and RV plus Intraocular Inflammation (IOI) in patients treated with aflibercept 2mg injections, providing crucial insights into the safety profile of this widely used therapy.

Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies
Oct 10, 2025

Regeneron Pharmaceuticals recently updated its clinical study investigating the safety and tolerability of odronextamab, officially titled ‘An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)’. The study aims to assess the potential of odronextamab in treating CD20+ B-cell malignancies, such as Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia, which are significant due to their prevalence and treatment challenges.

Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study
Oct 9, 2025

Study Overview: Alnylam Pharmaceuticals, in collaboration with Regeneron Pharmaceuticals, is conducting a Phase 1 study titled A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer’s Disease. The study aims to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of ALN-5288 in patients with Alzheimer’s Disease, marking a significant step in addressing this challenging condition.

Regeneron’s Innovative Cancer Study: A Potential Game-Changer for Advanced Tumors
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and optimal dosing of REGN7075, alone and in combination with cemiplimab, for treating advanced solid tumors. This research is significant as it explores new treatment avenues for difficult-to-treat cancers.

Regeneron Advances Melanoma Treatment with Long-term Study Update
Sep 7, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a study titled ‘Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613.’ The study aims to evaluate the long-term safety and effectiveness of the drug combination fianlimab and cemiplimab in patients with advanced melanoma. This research is significant as it seeks to understand the prolonged impact of these treatments on patient health and cancer progression.

Regeneron’s Latest Clinical Study on Advanced NSCLC: A Potential Game Changer?
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels.’ The study aims to evaluate the effectiveness of combining fianlimab with cemiplimab and chemotherapy compared to the combination of cemiplimab and chemotherapy alone in treating advanced NSCLC.

Regeneron’s Promising NSCLC Study: A Game Changer in Cancer Treatment?
Sep 7, 2025

Regeneron Pharmaceuticals is currently conducting a study titled ‘A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%’. The study aims to evaluate the effectiveness of combining fianlimab with cemiplimab compared to cemiplimab alone in treating advanced NSCLC, focusing on treatment efficacy, side effects, and quality of life improvements.

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for Genetic Disorders
Sep 7, 2025

Study Overview: The MAGNITUDE-2 study, officially titled A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN), aims to assess the efficacy and safety of NTLA-2001. This study is significant as it targets a genetic disorder affecting the nervous system, potentially offering new hope for patients with ATTRv-PN.

Regeneron’s Phase 2 Melanoma Study: A Potential Game-Changer in Cancer Treatment
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma. The study aims to evaluate the effectiveness of combining fianlimab and cemiplimab versus using cemiplimab alone in treating high-risk, resectable melanoma. The study’s significance lies in its potential to enhance treatment outcomes for melanoma patients.

Regeneron’s Linvoseltamab: A Promising Study for High-Risk Multiple Myeloma
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 study titled ‘Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma.’ This study aims to evaluate the safety and effectiveness of linvoseltamab in preventing the progression of high-risk smoldering multiple myeloma (HR-SMM) to multiple myeloma (MM). The significance of this study lies in its potential to offer a new therapeutic option for patients at high risk of developing MM.

Regeneron’s Linvoseltamab Study: A Potential Game-Changer in Multiple Myeloma Prevention
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma. The study aims to assess the effectiveness of linvoseltamab in eliminating abnormal plasma cells in patients at moderate risk of developing multiple myeloma, focusing on those with precancerous conditions like HR-MGUS and NHR-SMM.

Regeneron’s Linvoseltamab Study: A Potential Game-Changer for AL Amyloidosis
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis.’ The study aims to evaluate the safety and efficacy of linvoseltamab, an experimental drug, in treating patients whose AL amyloidosis has returned or is unresponsive to other treatments. This research is significant as it explores potential new treatment avenues for a challenging condition.

Regeneron’s Linvoseltamab Study: A Potential Game-Changer for Multiple Myeloma Treatment
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 1/2 study titled ‘Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma.’ The study aims to evaluate the safety and optimal dosing of linvoseltamab, a potential treatment for multiple myeloma, while also assessing its efficacy in combating cancer. The significance of this study lies in its potential to offer new therapeutic options for patients with relapsed or refractory multiple myeloma.

Regeneron Launches Phase 2 Study on Promising NSCLC Treatments
Sep 7, 2025

Regeneron Pharmaceuticals is launching a Phase 2 clinical study titled ‘A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).’ The study aims to evaluate the effectiveness and safety of two drugs, ubamatamab and REGN7075, in treating advanced or metastatic NSCLC. Additionally, the study will assess the use of sarilumab to manage immune-related side effects associated with ubamatamab.

Regeneron’s New Study on PNH Treatment: A Potential Game-Changer?
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a study titled A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy. The study aims to assess the effectiveness and safety of a combination of two experimental drugs, pozelimab and cemdisiran, in treating Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients who have not responded well to existing C5 inhibitors.

Regeneron and Intellia’s MAGNITUDE Study: A New Hope for ATTR-CM Treatment
Sep 7, 2025

Study Overview: The MAGNITUDE study, officially titled MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM), aims to assess the efficacy and safety of NTLA-2001. This study is significant as it targets Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM), a condition that affects the heart and can lead to severe health issues.

Regeneron’s Promising Phase 1 Trial for Aggressive B-Cell Lymphomas
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 1 clinical trial titled ‘A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)’. The study aims to evaluate the safety and tolerability of the experimental drugs REGN5837 and odronextamab in treating aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs), with the goal of determining the recommended dose for phase 2 trials.

Regeneron’s Linvoseltamab Study: A New Hope for Multiple Myeloma?
Sep 7, 2025

Regeneron Pharmaceuticals is currently conducting a clinical study titled ‘Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma.’ The study aims to evaluate the safety, tolerability, and effectiveness of linvoseltamab in adults with newly diagnosed multiple myeloma who have not yet received treatment. This research is significant as it explores a potential new treatment avenue for multiple myeloma, a challenging condition to treat effectively.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis
Sep 7, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 2 clinical study titled ‘A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis.’ The study aims to evaluate how well dupilumab works in treating eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD), focusing on symptom relief and inflammation reduction over a period of 24 to 52 weeks.

Regeneron Pharmaceuticals Takes Aim at Rare Pediatric Disease with New Clinical Study
Sep 7, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a clinical study titled An Open-Label, Single-Arm Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Pozelimab in Pediatric Patients 1 to 5 Years of Age With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease). The study aims to assess the safety and tolerability of the drug pozelimab in young children suffering from CHAPLE, a rare and potentially life-threatening hereditary disease affecting the gastrointestinal and cardiovascular systems.

Regeneron’s Hemophilia B Study: A Step Towards Future Therapies
Sep 7, 2025

Regeneron Pharmaceuticals is conducting a study titled ‘A Prospective Study to Evaluate Disease Characteristics in Hemophilia B Participants Receiving Prophylaxis With Standard of Care FIX Replacement Therapy.’ The study aims to gather comprehensive data on bleeding events in adult males with Hemophilia B who are on standard FIX replacement therapy. This observational study is significant as it seeks to understand individual disease characteristics and could inform future experimental therapies.

Regeneron’s Gene Silencing Study Targets Chronic Liver Disease
Sep 5, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors.’ The study aims to evaluate the effects of the investigational drug ALN-HSD on reducing liver scarring in patients with MASH, a chronic liver disease. This research is significant as it targets a condition that can lead to severe liver damage and failure.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric EoE
Sep 4, 2025

Study Overview: Regeneron Pharmaceuticals and Sanofi are conducting a study titled A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis. The study aims to assess the safety, tolerability, and effectiveness of dupilumab in treating eosinophilic esophagitis (EoE) in small children, a condition that affects feeding and nourishment.

Regeneron’s Phase 2 Study on Blood Clot Prevention: A Potential Game-Changer?
Aug 29, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH). The study aims to evaluate the effectiveness and safety of two experimental drugs, REGN9933 and REGN7508, in preventing venous thromboembolism (VTE) in adults with a peripherally inserted central catheter (PICC).

Regeneron’s Heart Failure Study: A Potential Game-Changer?
Aug 29, 2025

Regeneron Pharmaceuticals is conducting a study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. The study aims to assess the safety, tolerability, and effectiveness of REGN5381 in patients with heart failure, focusing on side effects, drug levels in the blood, and antibody development against the drug.

Regeneron and Sanofi’s DUPIXENT® Study: A Closer Look at EoE Treatment
Aug 29, 2025

Regeneron Pharmaceuticals and Sanofi are conducting an observational study titled A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care. The study aims to understand the real-world application of DUPIXENT® (dupilumab) in treating patients with eosinophilic esophagitis (EoE), focusing on patient experiences and outcomes.

Regeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in Thromboprophylaxis
Aug 29, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)’. The study aims to assess the efficacy of REGN7508 in preventing venous thromboembolism (VTE) in adults undergoing total knee replacement surgery, along with evaluating potential side effects, drug levels in the blood, and antibody development against the drug.

Regeneron’s Promising Study on REGN7999 for Iron Overload in Beta-Thalassemia
Aug 28, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (an Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia. The study aims to assess the safety and effectiveness of REGN7999 in reducing iron overload in patients with non-transfusion dependent beta-thalassemia, using MRI scans to measure iron levels.

Regeneron’s REGN7544: A Promising Treatment for Sepsis-Induced Hypotension?
Aug 28, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients With Sepsis-Induced Hypotension. The study aims to evaluate the safety, tolerability, and effectiveness of REGN7544 in treating adult patients with sepsis-induced hypotension, focusing on its impact on blood pressure and vasopressor dosage.

Regeneron’s Linvoseltamab Study: A New Hope for Resistant Multiple Myeloma
Aug 28, 2025

Regeneron Pharmaceuticals is conducting a Phase 1b clinical study titled ‘Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and optimal dosage of linvoseltamab when combined with other cancer treatments for patients with multiple myeloma that is resistant to standard therapies. This research is significant as it explores new treatment combinations for a challenging condition.

Regeneron’s Promising Phase 2 Study on Ovarian Cancer Treatment
Aug 28, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 study titled ‘Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer.’ The study aims to evaluate the safety, tolerability, and effectiveness of ubamatamab, alone and in combination with other anti-cancer drugs, in patients with advanced ovarian cancer. This research could provide significant insights into new treatment options for this challenging condition.

Regeneron’s Innovative Approach: Pozelimab and Cemdisiran in PNH Treatment
Aug 28, 2025

Regeneron Pharmaceuticals is conducting a study titled A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy. The study aims to assess the safety and effectiveness of the pozelimab and cemdisiran combination in treating Paroxysmal Nocturnal Hemoglobinuria (PNH) compared to existing treatments ravulizumab and eculizumab.

Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
Aug 27, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)’. The study aims to evaluate the safety, tolerability, and efficacy of odronextamab combined with chemotherapy compared to the standard treatment of rituximab with chemotherapy in patients with follicular lymphoma, a type of non-Hodgkin lymphoma.

Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
Aug 27, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 3 randomized study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).’ The study aims to evaluate the efficacy of cemiplimab, an immune-boosting drug, compared to standard surgical treatment for early-stage CSCC. This research is significant as it explores a less invasive treatment option that could potentially improve patient outcomes.

Regeneron Advances in AMD Treatment: A Closer Look at the Ongoing Clinical Study
Aug 27, 2025

Regeneron Pharmaceuticals is currently conducting a Phase 3 clinical study titled ‘A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration.’ The study aims to evaluate the progression rate of Geographic Atrophy in patients treated with cemdisiran alone or in combination with pozelimab compared to a placebo, with a focus on safety, drug levels in the blood, and potential antibody development.

Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game-Changer?
Aug 25, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 trial titled A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC. The study aims to evaluate the safety and efficacy of combining fianlimab, cemiplimab, and chemotherapy compared to cemiplimab and chemotherapy alone in treating resectable non-small cell lung cancer (NSCLC). This research is significant as it explores potential improvements in peri-operative therapy for NSCLC patients.

Regeneron’s Innovative Gene Therapy Study for Hemophilia B: Market Implications and Progress
Aug 24, 2025

Regeneron Pharmaceuticals is conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a novel gene insertion therapy, REGV131-LNP1265, designed to enable long-term production of clotting factor in patients with hemophilia B, potentially reducing the need for regular factor replacement therapy.

Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: What Investors Need to Know
Aug 24, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma. The study aims to evaluate the safety and efficacy of odronextamab, an experimental bispecific antibody, combined with lenalidomide, compared to the current standard treatment of rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma. This research is significant as it explores a potentially more effective treatment option for these lymphoma subtypes.

Regeneron’s Real-World Study on Aflibercept: Market Implications and Investor Insights
Aug 24, 2025

Regeneron Pharmaceuticals is conducting a real-world evidence study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aims to estimate the incidence of retinal vasculitis (RV) events in patients receiving aflibercept intravitreal (IVT) therapy, commonly known as Eylea® 2mg, in US clinical practice. This research is significant as it seeks to confirm RV cases identified through ICD-10-CM codes and identify RV with occlusion.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Pediatric Prurigo Nodularis
Aug 24, 2025

Study Overview: The clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis aims to evaluate the pharmacokinetics and safety of Dupilumab in young participants suffering from Prurigo Nodularis. This study is significant as it targets a pediatric population, potentially expanding treatment options for this chronic skin condition.

Regeneron’s PNH Study: A Promising Step in Rare Disease Treatment
Aug 24, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a study titled An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria. The study aims to assess the long-term safety and effectiveness of the pozelimab and cemdisiran combination therapy in treating Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disorder. This research is significant as it explores potential new treatment options for PNH patients.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
Aug 22, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis. The study aims to evaluate the pharmacokinetics and safety of Dupilumab in young participants suffering from Prurigo Nodularis, a chronic skin condition. This research is significant as it could lead to new treatment options for a demographic that currently has limited therapeutic choices.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
Aug 22, 2025

Study Overview: Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for individuals with hemophilia B, a condition caused by a genetic mutation in the coagulation Factor 9 gene. The primary goal is to determine a safe and well-tolerated dose of the therapy, with secondary objectives including the assessment of drug presence in the blood, antibody formation, and the impact on quality of life and joint health.

Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: A Closer Look
Aug 21, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)’. The study aims to determine if the combination of odronextamab and lenalidomide is more effective and safer than the current standard treatment of rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL).

Regeneron’s Real-World Study on Aflibercept: Key Insights for Investors
Aug 21, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aims to estimate the incidence of retinal vasculitis (RV) among adult patients receiving aflibercept 2 mg in the United States. This research is significant as it seeks to provide real-world insights into the safety profile of aflibercept, a drug widely used in ophthalmology.

Regeneron and Sanofi’s Itepekimab Study: A Potential Game-Changer for COPD Treatment
Aug 21, 2025

The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects on airway inflammation in patients with Chronic Obstructive Pulmonary Disease (COPD). Officially titled ‘A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)’, the study aims to explore the drug’s mechanism in former and current smokers with COPD, highlighting its significance in potentially advancing COPD treatment options.

Regeneron’s PNH Study: Long-Term Safety and Efficacy of Pozelimab + Cemdisiran
Aug 20, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a study titled An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria. The study aims to assess the long-term safety and effectiveness of a combination therapy using pozelimab and cemdisiran in treating patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Prurigo Nodularis
Aug 20, 2025

Study Overview: The clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis aims to evaluate the pharmacokinetics and safety of Dupilumab in young patients with Prurigo Nodularis. This study is significant as it addresses a pediatric population for a condition that lacks extensive treatment options.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Chronic Urticaria
Aug 20, 2025

The recently completed clinical study titled ‘Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab’ aimed to demonstrate the efficacy of dupilumab in treating chronic spontaneous urticaria (CSU) in patients who remain symptomatic despite H1 antihistamine use. The study’s significance lies in its potential to offer a new treatment option for CSU patients who do not respond adequately to existing therapies.

Regeneron’s Promising PNH Treatment Study: A Potential Game-Changer?
Aug 19, 2025

Regeneron Pharmaceuticals is conducting a study titled ‘An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria.’ The study aims to assess the long-term safety and effectiveness of the pozelimab and cemdisiran combination in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This research is significant as it explores potential new treatments for PNH, focusing on safety, efficacy, and the body’s response to the drugs.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer
Aug 15, 2025

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for hemophilia B, focusing on finding a safe and well-tolerated dose while assessing various health impacts on participants.

Regeneron’s Cemiplimab: A New Hope for Early-Stage Skin Cancer?
Aug 15, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 3 randomized study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)’. The study aims to evaluate the efficacy of cemiplimab, an immune-boosting drug, compared to traditional surgery in treating early-stage CSCC, a common form of skin cancer. This research is significant as it explores a potentially less invasive treatment option for patients.

Regeneron Advances in Cancer Treatment with SNS-101 Study Update
Aug 15, 2025

Regeneron Pharmaceuticals, in collaboration with Sensei Biotherapeutics, is conducting a Phase 1/2 study titled A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors. The study aims to assess the safety and efficacy of SNS-101, a novel anti-VISTA IgG1 monoclonal antibody, both as a standalone treatment and in combination with cemiplimab for patients with advanced solid tumors.

Regeneron’s Phase 3 Study on Garetosmab: A Potential Game-Changer for FOP Treatment
Aug 15, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)’. The study aims to evaluate the safety and effectiveness of garetosmab, an experimental drug, in treating FOP, a rare and debilitating condition. The study also investigates potential side effects, drug levels in the blood, and the body’s immune response to the drug.

Regeneron’s Phase 2 Trial: A Potential Game-Changer in Blood Clot Prevention
Aug 14, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 2 clinical trial titled A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH). The study aims to evaluate the effectiveness and safety of two experimental drugs, REGN9933 and REGN7508, in preventing venous thromboembolism (VTE) in adults with a peripherally inserted central catheter (PICC). The study also explores potential side effects and the body’s antibody response to the drugs.

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN
Aug 14, 2025

Regeneron Pharmaceuticals and Intellia Therapeutics have launched a Phase 3 clinical study titled ‘MAGNITUDE-2’ to assess the efficacy and safety of NTLA-2001 in treating hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This study is crucial as it explores a potential breakthrough treatment for a debilitating genetic disorder.

Regeneron’s Promising Study on Platinum-Resistant Ovarian Cancer
Aug 14, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled ‘Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer.’ The study aims to evaluate the safety, tolerability, and effectiveness of ubamatamab, both alone and in combination with other anti-cancer drugs, in patients with advanced ovarian cancer. This research is significant as it targets platinum-resistant ovarian cancer, a challenging condition to treat.

Regeneron’s Latest Clinical Trial: A New Hope for Advanced Cancer Treatment
Aug 13, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 1/2 clinical trial titled A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of REGN7075 alone and in combination with cemiplimab, with or without chemotherapy, in patients with advanced solid tumors. The significance lies in potentially offering new treatment avenues for difficult-to-treat cancers.

Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
Aug 13, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical study titled ‘A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).’ The study aims to evaluate the effectiveness of cemiplimab, an immunotherapy drug, compared to standard surgical treatment for early-stage CSCC. This research is significant as it explores a less invasive treatment option that could enhance patient outcomes and potentially reduce recovery times.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer?
Aug 13, 2025

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for individuals with hemophilia B, focusing on finding a safe dose and assessing the therapy’s impact on quality of life, joint health, and the need for factor replacement therapy.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Asthma Treatment
Aug 8, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a study titled A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma. The study aims to evaluate the effectiveness of Dupilumab in preventing or slowing lung function decline in adults with uncontrolled moderate to severe asthma, highlighting its potential significance in improving patient outcomes.

Regeneron and Sanofi’s Dupilumab Trial: A Potential Game-Changer for Ulcerative Colitis
Aug 8, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 2 clinical trial titled ‘A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype.’ The study aims to evaluate the effectiveness and safety of Dupilumab in treating ulcerative colitis with an eosinophilic phenotype, a condition that significantly impacts patients’ quality of life.

Regeneron’s Promising Phase 3 Melanoma Study: A Potential Game-Changer?
Aug 8, 2025

Study Overview: Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma.’ The study aims to evaluate the safety and effectiveness of the experimental combination of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab in treating advanced melanoma.

Regeneron’s Phase 3 Study on Odronextamab: A Potential Game-Changer for B-cell Lymphoma
Aug 8, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4).’ The study aims to assess the safety, tolerability, and efficacy of odronextamab in patients with aggressive B-cell non-Hodgkin lymphoma that has relapsed or is refractory.

Regeneron’s Promising Immunotherapy Study for Advanced Lung Cancer
Aug 7, 2025

Regeneron Pharmaceuticals, in collaboration with Servier Bio-Innovation LLC and Institut de Recherches Internationales Servier, is conducting a Phase 1b/2 study titled A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression. The study aims to evaluate the safety and efficacy of the anti-PD1 antibody, cemiplimab, in combination with other antibodies (S095018, S095024, or S095029) in patients with advanced NSCLC.

Regeneron and Sanofi’s Phase 3 Itepekimab Study: A Potential Game Changer for CRSwNP Treatment
Aug 7, 2025

Study Overview: Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical trial titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. The study aims to assess the effectiveness, safety, and tolerability of Itepekimab, an anti-IL-33 monoclonal antibody, as an add-on therapy for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
Aug 7, 2025

The clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze aims to evaluate the effectiveness and safety of Dupilumab in young children. This study is significant as it addresses the need for effective treatments in this vulnerable age group with uncontrolled asthma.

Regeneron and Sanofi’s DUPIXENT® Study: A Boost for EoE Treatment Insights
Aug 7, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a study titled ‘A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care.’ The study aims to understand the use of DUPIXENT® (dupilumab) in treating eosinophilic esophagitis (EoE) and its impact on patients’ quality of life and symptoms. This research is significant as it could inform future treatment decisions and clinical trial designs for EoE.

Regeneron’s New ALS Study: A Potential Game-Changer for SOD1-ALS Treatment
Aug 7, 2025

Regeneron Pharmaceuticals is conducting a groundbreaking study titled ‘First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations.’ The study aims to assess the safety and tolerability of ALN-SOD, an experimental drug for ALS patients with SOD1 gene mutations, marking its first human trial.

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Lichen Simplex Chronicus
Aug 7, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled ‘A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1).’ The study aims to evaluate the efficacy and safety of Dupilumab in treating pruritus associated with Lichen Simplex Chronicus (LSC) in adults, highlighting its potential significance in addressing this chronic skin condition.

Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
Aug 7, 2025

Regeneron Pharmaceuticals is conducting a Phase 1 study titled ‘A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)’. The study aims to evaluate the safety and tolerability of cemiplimab, an experimental drug, in patients with CSCC or BCC. This research is significant as it explores potential new treatments for these skin cancers.

Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
Aug 7, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. The study aims to evaluate the efficacy, safety, and tolerability of Itepekimab, an anti-IL-33 monoclonal antibody, in treating chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.

Regeneron and Sanofi’s Promising Phase 3 Study on Dupilumab for LSC
Aug 7, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults.’ The study aims to evaluate the effectiveness of Dupilumab injections in reducing pruritus in adults with LSC, compared to a placebo. This research is significant as it explores a potential new treatment for a condition that currently has limited options.

Regeneron’s Latest Clinical Study: A New Hope for Advanced NSCLC Treatment
Aug 5, 2025

Regeneron Pharmaceuticals is involved in a Phase 1b/2 clinical study titled ‘A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression.’ The study aims to evaluate the safety and efficacy of the anti-PD1 antibody, cemiplimab, in combination with other antibodies in treating advanced NSCLC with high PD-L1 expression.

Regeneron Pharmaceuticals Reports Strong Q2 2025 Results
Aug 2, 2025

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for serious diseases, with a focus on eye diseases, allergic and inflammatory diseases, cancer, and other conditions. The company is known for its innovative approach to drug development, utilizing proprietary technologies to create life-transforming treatments.

Regeneron Earnings Call: Growth Amid Challenges
Aug 2, 2025

Regeneron Pharmaceuticals’ recent earnings call reflected a balanced sentiment, highlighting both achievements and challenges. The company reported strong sales growth for Dupixent and Libtayo, alongside promising pipeline advancements. However, hurdles such as a decline in EYLEA sales and regulatory delays due to FDA inspections were also discussed.

Regeneron’s New Study on MASH: A Potential Game-Changer?
Aug 1, 2025

Regeneron Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors.’ The study aims to evaluate the effectiveness of a new drug, ALN-HSD, in reducing liver scarring in patients with MASH, a severe liver condition linked to genetic factors.

Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game Changer?
Aug 1, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)’. The study aims to evaluate the safety, tolerability, and efficacy of odronextamab combined with chemotherapy compared to the current standard treatment of rituximab with chemotherapy in patients with follicular lymphoma.

Regeneron and Sanofi’s Dupilumab Study: A Real-World Asthma Treatment Analysis
Aug 1, 2025

The clinical study titled ‘PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting’ aims to evaluate the characteristics and treatment patterns of asthma patients using Dupilumab (DUPIXENT). The study’s primary objective is to characterize patients’ medical history, socio-demographic data, and treatment history. It also seeks to assess the effectiveness and safety of Dupilumab in real-world settings, making it significant for understanding its practical application and impact on asthma management.

Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment
Aug 1, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5). The study aims to evaluate the safety and efficacy of the experimental drug odronextamab combined with lenalidomide compared to the standard treatment of rituximab and lenalidomide in treating relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Regeneron’s Innovative Approach in NSCLC Treatment: A Promising Clinical Trial Update
Aug 1, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 clinical trial titled A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC. The study aims to evaluate the safety and efficacy of combining fianlimab with cemiplimab and chemotherapy compared to cemiplimab and chemotherapy alone in treating non-small cell lung cancer (NSCLC) that can be surgically removed.

Regeneron and Sanofi’s New COPD Study: What Investors Need to Know
Jul 31, 2025

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease.’ The study aims to assess the impact of Dupilumab on airway inflammation, lung function, and quality of life in patients aged 40 to 85 with COPD.

Regeneron’s Linvoseltamab Study: A New Hope for Multiple Myeloma Treatment
Jul 31, 2025

Regeneron Pharmaceuticals is conducting a Phase 1b study titled ‘Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and appropriate dosing of linvoseltamab, an experimental drug, when combined with other cancer treatments for multiple myeloma patients who are resistant to standard care.

Regeneron’s Mibavademab Study: A New Hope for GLD Treatment?
Jul 31, 2025

Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Metreleptin to Mibavademab, A Leptin Receptor Agonist Antibody.’ The study aims to evaluate the safety and tolerability of mibavademab, an experimental drug, in patients with Generalized Lipodystrophy (GLD) who have been on metreleptin treatment for at least six months. The significance of this study lies in its potential to offer a new treatment option for GLD patients.

Regeneron Advances Heart Failure Treatment with New Clinical Study
Jul 31, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. The study aims to assess the safety, tolerability, and effectiveness of REGN5381 in patients with heart failure, focusing on potential side effects and the body’s response to the drug.

Regeneron Completes Phase 1 Study on NAFLD Treatment with ALN-PNP
Jul 31, 2025

Regeneron Pharmaceuticals has completed a Phase 1 clinical study titled A Three-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-PNP siRNA in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a PNPLA3 Genetic Risk Factor. The study aimed to assess the safety, tolerability, and effectiveness of ALN-PNP in adults with NAFLD and a specific genetic risk factor.

Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment?
Jul 30, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)’. The study aims to evaluate the safety and efficacy of odronextamab combined with lenalidomide compared to the current standard treatment of rituximab with lenalidomide in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Regeneron’s Gene-Silencing Approach to Combat Liver Disease: A Clinical Study Update
Jul 30, 2025

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors.’ The study aims to evaluate the effectiveness of a gene-silencing drug, ALN-HSD, in reducing liver scarring in patients with MASH, a serious liver condition that can lead to cirrhosis and liver failure.

Regeneron’s Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
Jul 30, 2025

Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)’. The study aims to evaluate the safety, tolerability, and efficacy of odronextamab combined with chemotherapy compared to the standard treatment of rituximab with chemotherapy in adults with follicular lymphoma.

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN
Jul 30, 2025

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a Phase 3 clinical study titled ‘MAGNITUDE-2’ to evaluate the efficacy and safety of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This study aims to assess the impact of a single dose of NTLA-2001 compared to a placebo, highlighting its potential significance in treating this rare genetic disorder.

Regeneron and Sanofi’s Real-World Asthma Study: A Potential Game Changer
Jul 30, 2025

Regeneron Pharmaceuticals and Sanofi are conducting a study titled ‘PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting.’ The study aims to understand the characteristics of asthma patients treated with Dupixent, focusing on their medical history, treatment patterns, and effectiveness of the drug in real-world settings. This research holds significance for improving asthma treatment strategies and patient outcomes.

Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM
Jul 30, 2025

The recent clinical study titled ‘MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)’ aims to evaluate the efficacy and safety of NTLA-2001. This study is significant as it targets ATTR-CM, a condition with limited treatment options, potentially offering a new therapeutic pathway.

Regeneron and Sanofi’s New COPD Study: Key Insights for Investors
Jul 29, 2025

Study Overview: Regeneron Pharmaceuticals and Sanofi are collaborating on a clinical study titled A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease. The study aims to assess the impact of Dupilumab on airway inflammation and lung function in patients aged 40 to 85 with COPD, highlighting its potential to improve quality of life.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025